USC Norris Comprehensive
Welcome,         Profile    Billing    Logout  
 0 Trials 
22 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Menendez, Xiomara
XTX202-01, NCT05052268 / 2022-003078-21: XTX202 in Patients With Advanced Solid Tumors

Active, not recruiting
1/2
189
US
XTX202
Xilio Development, Inc., Xilio Development, Inc
Advanced Solid Tumor
02/26
02/26
NCT03520075 / 2018-004568-72: Study of ASTX029 in Subjects With Advanced Solid Tumors

Active, not recruiting
1/2
190
Europe, US
ASTX029
Taiho Oncology, Inc.
Solid Tumor, Adult
08/24
12/25
NCT04092673: Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

Recruiting
1/2
30
US
eFT226, Selective translation inhibitor, Sotorasib, Lumarkus, Fulvestrant, Faslodex, Abemaciclib, Verzenia, Trastuzumab, Herceptin
Effector Therapeutics
Solid Tumor, Adult
12/24
03/25
GLIMMER-01, NCT05259696: Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein

Active, not recruiting
1/2
273
US
E-602, Cemiplimab, Libtayo, REGN2810
Palleon Pharmaceuticals, Inc.
Oncology, Melanoma, Ovarian Cancer, NSCLC, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Cancer, CRC, Colon Cancer, Breast Cancer, Gastric Cancer, EGJ, Esophagogastric Junction Cancer, Head and Neck Cancer, Urothelial Cancer, Bladder Cancer
06/25
06/25
NCT05099549: Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers

Terminated
1/2
11
US
AFM24, SNK01
NKGen Biotech, Inc., Affimed GmbH
Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Advanced Solid Tumor, Refractory Tumor, Metastatic Tumor
09/23
09/23
NCT05902988: A Phase I/II Study of VLS-1488 in Subjects with Advanced Cancer

Recruiting
1/2
120
US
VLS-1488
Volastra Therapeutics, Inc.
Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer, Gastric Adenocarcinoma, Colorectal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Transitional Cell Carcinoma of Bladder, Head and Neck Squamous Cell Carcinoma, Ovarian Carcinosarcoma, Uterine Carcinosarcoma, Uterine Serous Carcinoma, Endometrium Cancer, Chromosomal Instability
12/25
06/26
AFNT211-22-101, NCT06105021: Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects with Advanced or Metastatic Solid Tumor

Recruiting
1/2
100
US
AFNT-211
Affini-T Therapeutics, Inc.
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, KRAS G12V
12/25
12/29
TACTIC-3, NCT05862324: TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors

Recruiting
1/2
113
Canada, US
TAC01-CLDN18.2
Triumvira Immunologics, Inc.
Metastatic Solid Tumor
08/27
08/27
KEYNOTE-C16, NCT04374877: Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Recruiting
1
260
US, RoW
CHS-388, Casdozokitug, Pembrolizumab, Keytruda®, Toripalimab, Loqtorzi®
Coherus Biosciences, Inc., Merck Sharp & Dohme LLC
Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
12/25
08/26
TEAD-AST-101, NCT06251310: SW-682 in Advanced Solid Tumors

Recruiting
1
186
US
SW-682, Combination Therapy
SpringWorks Therapeutics, Inc.
Advanced Solid Tumor, Mesothelioma, Malignant
01/30
06/30
NCT03872947: A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Recruiting
1
187
Europe, US
TRK-950, Irinotecan, Leucovorin, 5-FU, Gemcitabine, Cisplatin, Carboplatin, Ramucirumab, Paclitaxel, Nivolumab, Pembrolizumab, Imiquimod Cream, Bevacizumab, PLD
Toray Industries, Inc
Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
03/25
03/25
NX-1607-101, NCT05107674: A Study of NX-1607 in Adults With Advanced Malignancies

Recruiting
1
345
Europe, US
NX-1607, Cbl-b Inhibitor, Paclitaxel
Nurix Therapeutics, Inc.
Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma
08/26
02/28
SRN-707-001, NCT05037149: Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors

Active, not recruiting
1
50
US
STP707, STP707 Powder for Injection
Sirnaomics
Solid Tumor
03/24
03/24
STEALTH-001, NCT06444815: A Study of VET3-TGI in Patients With Solid Tumors

Recruiting
1
60
US
VET3-TGI, Pembrolizumab
KaliVir Immunotherapeutics
Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Kidney Cancer, Renal Cell Carcinoma, Melanoma Stage IV, Merkel Cell Carcinoma of Skin, Mesothelioma, Non-small Cell Lung Cancer
09/27
12/27
NCT05808634: Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.

Recruiting
1
168
US
BA3182
BioAtla, Inc.
Advanced Adenocarcinoma
06/25
12/25
C-1100-01, NCT04121676: Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer

Completed
1
91
US
AGEN2373, Anti-CD137, Botensilimab, AGEN1181, Anti-CTLA-4
Agenus Inc.
Advanced Cancer
02/24
11/24
TOS-358-001, NCT05683418: A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults with Select Solid Tumors

Recruiting
1
241
Europe, US
TOS-358
Totus Medicines
Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Endometrial Cancer, HR+/HER2-negative Breast Cancer
12/25
12/25
NCT05791448: AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease

Recruiting
1
36
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, RNA Transcription Modulator AU-409, AU 409, AU-409, AU409
University of Southern California, National Cancer Institute (NCI), Auransa, Inc.
Advanced Cholangiocarcinoma, Advanced Hepatocellular Carcinoma, Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Liver, Refractory Malignant Solid Neoplasm, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
03/26
03/27
ST316-101, NCT05848739: A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

Recruiting
1
130
US
ST316, FOLFIRI regimen & bevacizumab, FOLFIRI, Fruquintinib, Lonsurf & bevacizumab
Sapience Therapeutics
Colon Cancer, Metastatic Colon Cancer
05/26
05/27
FIT-001, NCT06026410: KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Recruiting
1
270
US
KO-2806, Cabozantinib, Cabometyx, Adagrasib, Krazati
Kura Oncology, Inc., Mirati Therapeutics Inc.
Solid Tumors with HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Clear Cell Renal Cell Carcinoma (ccRCC), Renal Cell Carcinoma (Kidney Cancer)
01/27
04/27
NCT05377528: Study of AGEN1571 in Participants With Advanced Solid Tumors

Active, not recruiting
1
22
US
AGEN1571, Balstilimab, AGEN2034, Botensilimab, AGEN1181
Agenus Inc.
Advanced Solid Tumor
01/27
01/27
NCT05230186: A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.

Recruiting
N/A
200
US
Tumor Biopsy, Excess tissue during planned surgical procedure
TScan Therapeutics, Inc.
Solid Tumor, Adult
12/24
12/24

Download Options